AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has received approval from the New York State Department of Health’s (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) for OvaWatch®, the Company’s non-invasive blood test for the assessment of ovarian cancer risk for women with an adnexal mass determined by initial ...

Annex Insurance (AWH, Financial) stock recently experienced a sharp decline, dropping 7.47% to $0.761 per share. The trading volume stood at 16,266 shares, with a turnover rate of 0.10% and a price fluctuation of 2.62%.Recent financial reports show Annex Insurance faced significant challenges, recording a revenue of $2.42 million but a net loss of $3.53 million. Earnings per share were reported at -$0.28, with a gross profit of $1.42 million and a negative price-to-earnings ratio of -0.58. Currently, no ins ...

Aspira Womens Health (AWH, Financial) experienced a significant stock price drop of 7.80%, reaching $0.775 per share. The trading volume stood at 14,064 shares with a turnover rate of 0.09% and a volatility of 7.47%.Recent financial results for Aspira Womens Health revealed an operating revenue of $2.42 million and a net loss of $3.53 million, resulting in an earnings per share (EPS) of -$0.28. The gross profit was recorded at $1.42 million, with a price-to-earnings ratio of -0.57. Currently, no institution ...

Core Insights - Aspira Women's Health Inc. has entered a strategic partnership with Dorsata to develop a custom protocol workflow tool aimed at improving the management of adnexal masses [1][2] - The partnership seeks to standardize care and enhance patient outcomes by addressing the challenges in diagnosing and treating adnexal masses, which include ovarian cysts and other growths [2][3] - The integration of the new Module into Dorsata's electronic medical records system is expected to streamline diagnosis and treatment processes while aggregating clinical data for better analysis and outcomes [3] Company Developments - The Module's deployment is anticipated to begin by late 2024, marking a significant advancement in clinical practices for women's health [1] - Aspira's collaboration with over 250 obstetrics and gynecology physicians aims to ensure consistent care across various healthcare settings [2] - The partnership is expected to refine diagnostic and treatment protocols, potentially leading to early identification of ovarian cancer risks [3] Market Outlook - The global ovarian cancer treatment market is projected to grow from $2.50 billion in 2023 to $5.45 billion by 2033, reflecting an 8.10% CAGR [4][5] - Innovations in treatment, such as PARP inhibitors and anti-angiogenic therapies, are expected to enhance efficacy and drive market expansion [4][5] Share Performance - Aspira's shares have decreased by 74.8% year to date, contrasting with a 10% growth in the industry [6] - The company currently holds a Zacks Rank of 3 (Hold), indicating a cautious outlook compared to better-ranked stocks in the medical sector [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------|-------------------------------------------| | | | | For the transition | ______ | | Commission | 001-34810 | | As ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Nicole Sandford - CEO and Director Sandy Milligan - President Conference Call Participants Ross Osborn - Cantor Fitzgerald Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen. And welcome to Aspira Women's Health, Incorporated Second Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. As a reminder, this is call being record ...

Aspira (AWH) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this diagnostic and bio-analytical company would post a loss of $0.36 per share when it actually produced a loss of $0.39, delivering a surprise of -8.33%.Over the last four quarters, the ...

Aspira Women's Health Reports Second Quarter 2024 Financial Results Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, August 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq: AWH), a bio-analytical based women's health company focused on the developme ...

Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financi ...

Achieved $141.5M Net Revenue in Q2 2024, a 15% Increase Year-Over-Year Reported $28.3 million in Adjusted EBITDA, a 33% Increase Year-Over-Year  Generated Positive Cash from Operations and Free Cash FlowNEW YORK, Aug. 5, 2024 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," or the "Company" or "Ascend") (CSE: AAWH.U) (OTCQX: AAWH), a vertically integrated multi-state cannabis operator focused on bettering lives through cannabis, today reported its financial results for the three months ended June 30, 2 ...